Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

The report’s authors found that Pfizer’s antiviral medication Paxlovid offered little to no benefit for younger adults. However, it did reduce the risk of hospitalization for high-risk seniors. Notably, supplementary material from the original study of Paxlovid in high-risk non-hospitalized adults with COVID-19 during the Delta wave had demonstrated benefits in those younger than 65, albeit the difference compared to the placebo was much less than in those 65 and older.

Among those over 65, there was a 73 percent decrease in the hospitalization rate and a 79 percent reduction in the risk of death. However, patients between the ages of 40 and 65 saw no benefit in taking the antiviral medication in either category, regardless of previous immunity status.

Another critical study from Hong Kong published in Lancet Infectious Diseases on the same day as the Israeli study but which went unmentioned in the press offered further evidence of Paxlovid’s limited therapeutic role. The authors reviewed their clinical experience with Paxlovid and Lagevrio, Merck’s antiviral pill, Molnupiravir, in hospitalized patients. They compared them to hospitalized patients who did not receive those medications during the horrific wave of infections that slammed into the semi-autonomous region in February and March.

The mortality risk reduction for Lagevrio was 52 percent, and for Paxlovid it was 66 percent. Those receiving antivirals had a lower risk of their disease progressing, but the drugs did not significantly impact their need for mechanical ventilation or ICU admission. The patients in the study averaged in age from mid-70s to early 80s.

Given the results of these studies, it bears mentioning that the Centers for Disease Control and Prevention (CDC) has recently estimated that approximately 95 percent of Americans aged 16 and older have some level of immunity against COVID-19.

Biden tests positive for COVID-19, has ‘very mild symptoms’

By ZEKE MILLER and CHRIS MEGERIAN, Associated Press

WASHINGTON (AP) — President Joe Biden tested positive for COVID-19 on Thursday and is experiencing “very mild symptoms,” the White House said, as new variants of the highly contagious virus are challenging the nation’s efforts to get back to normal after two and a half years of pandemic disruptions.

Biden tests positive for COVID-19, has ‘very mild symptoms’

DOUBLE-BOOSTED Fauci’s Covid WORSENS After Paxlovid Rebound.

Related:

Fauci Says He Had Paxlovid Rebound, Worse Symptoms:

Fauci first tested positive after having a “scratchy throat,” he told the newspaper. After taking Paxlovid, he was “surprised and disappointed” to see he tested positive again, and he had symptoms such as a low fever, achiness, runny nose, and “mild cough.” He then called his doctor, who prescribed another 5-day course of Paxlovid, which Fauci said is relatively common among those who have a rebound.

Earlier this month, Pfizer, the maker of Paxlovid, announced that it would stop adding new people to a clinical trial of the drug among COVID-19 patients who have a low risk of hospitalization and death. The study failed to show that the drug reduced symptoms, hospitalizations, or deaths in a statistically significant way, Bloomberg reported.

COVID-19 Rebound After Paxlovid Treatment:

There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected.

Going against CDC guidance, huh?! Hypocrite!